<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04391439</url>
  </required_header>
  <id_info>
    <org_study_id>IVMPheartrate</org_study_id>
    <nct_id>NCT04391439</nct_id>
  </id_info>
  <brief_title>Heart Rhythm After Intravenous Methylprednisolone Administration</brief_title>
  <official_title>Increased Heart Rhythm in Response to High-dose Intravenous Methylprednisolone Pulse Therapy of Moderate-to-severe Graves' Orbitopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      High doses of intravenous (iv.) glucocorticoids (GCs) are commonly used as a treatment for
      many autoimmune and inflammatory disorders. According to the European Group on Graves'
      Orbitopathy (EUGOGO) guidelines, intravenous methylprednisolone (IVMP) is an accepted
      first-line agent for active, moderate-to-severe and very severe Graves' orbitopathy (GO).
      This treatment is proven to be more efficient and safer than oral GCs. However, some patients
      may experience adverse cardiovascular effects during the administration of iv. GCs, which in
      rare cases may even be fatal. There are limited data, mostly obtained from case reports,
      reporting the occurrence of cardiac arrhythmias, acute myocardial infarction or heart
      failure. Increased heart rhythm (HR) has drawn attention of researchers as a possible adverse
      effect correlated with IVMP. During this study, investigators performed 72-hours of Holter
      ECG and ambulatory blood pressure monitoring (ABPM) to evaluate the impact of IVMP on
      patients with moderate-to-severe GO, concerning HR and blood pressure (BP) changes. In order
      to elucidate possible mechanism of observed changes, researchers investigated the level of
      potassium in serum and urine and catecholamines (epinephrine, norepinephrine) in serum. All
      patients were treated routinely according to EUGOGO recommendations with standard doses of
      methylprednisolone with standard recommended schedule. Inclusion criterion for the therapy
      was according to EUGOGO guidelines active, moderate-to-severe and active GO (12 pulses of
      IVMP 6x0.5g followed by 6x0.25g every week).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical status of patients was evaluated before each pulse, including blood pressure
      monitoring, glucose level monitoring and symptoms of infection. HR and BP was measured
      continuously for 3 consecutive days (the day before, the day of IVMP and the day after IVMP)
      during 1st, 6th and 12th IVMP pulse, using 24-hour Holter ECG and ABMP. Serum laboratory
      tests for potassium, epinephrine and norepinephrine were measured 3 times the day before and
      the day of first IVMP pulse and 1 time the second and sixth day after 1st IVMP. Additionally,
      urine samples for potassium were collected 5 times the day of first IVMP pulse and 1 time the
      second and sixth day after 1st IVMP.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2011</start_date>
  <completion_date type="Actual">February 20, 2020</completion_date>
  <primary_completion_date type="Actual">February 20, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>24-hour Holter ECG Monitoring - 1st pulse mean HR</measure>
    <time_frame>72 hours</time_frame>
    <description>Analysis of changes in mean HR between day before and day of 1st pulse of IVMP, day of 1st IVMP and day after 1st IVMP, day before and day after 1st IVMP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24-hour Holter ECG Monitoring - 6th pulse mean HR</measure>
    <time_frame>72 hours</time_frame>
    <description>Analysis of changes in mean HR between day before and day of 6th pulse of IVMP, day of 6th IVMP and day after 6th IVMP, day before and day after 6th IVMP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24-hour Holter ECG Monitoring - 12th mean HR</measure>
    <time_frame>72 hours</time_frame>
    <description>Analysis of changes in mean HR between day before and day of 12th pulse of IVMP, day of 12th IVMP and day after 12th IVMP, day before and day after 12th IVMP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum potassium levels Day 0 - Day 1</measure>
    <time_frame>48 hours</time_frame>
    <description>Change in value of potassium between day before and day of 1st pulse of IVMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum epinephrine levels Day 0 - Day 1</measure>
    <time_frame>48 hours</time_frame>
    <description>Change in value of epinephrine between day before and day of 1st pulse of IVMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum norepinephrine levels Day 0 - Day 1</measure>
    <time_frame>48 hours</time_frame>
    <description>Change in value of norepinephrine between day before and day of 1st pulse of IVMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine potassium levels Day 0</measure>
    <time_frame>24 hours</time_frame>
    <description>Change in value of potassium during the day of 1st pulse of IVMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>72-hour ambulatory blood pressure monitoring (ABPM) - 1st pulse mean BP</measure>
    <time_frame>72 hours</time_frame>
    <description>Analysis of changes in mean BP between day before and day of 1st pulse of IVMP, day of 1st IVMP and day after 1st IVMP, day before and day after 1st IVMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>72-hour ambulatory blood pressure monitoring (ABPM) - 6th pulse mean BP</measure>
    <time_frame>72 hours</time_frame>
    <description>Analysis of changes in mean BP between day before and day of 6th pulse of IVMP, day of 6th IVMP and day after 6th IVMP, day before and day after 6th IVMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>72-hour ambulatory blood pressure monitoring (ABPM) - 12th pulse mean BP</measure>
    <time_frame>72 hours</time_frame>
    <description>Analysis of changes in mean BP between day before and day of 12th pulse of IVMP, day of 12th IVMP and day after 12th IVMP, day before and day after 12th IVMP</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum potassium levels Day 0 - Day 7</measure>
    <time_frame>7 days</time_frame>
    <description>Change in value of potassium between day before and sixth day after 1st pulse of IVMP</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum potassium levels Day 0 - Day 2</measure>
    <time_frame>72 hours</time_frame>
    <description>Change in value of potassium between day of 1st IVMP and day after 1st IVMP, day before and day after 1st IVMP</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum epinephrine levels Day 0 - Day 7</measure>
    <time_frame>7 days</time_frame>
    <description>Change in value of epinephrine between day before and sixth day after 1st pulse of IVMP</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum epinephrine levels Day 0 - Day 2</measure>
    <time_frame>72 hours</time_frame>
    <description>Change in value of epinephrine between day of 1st IVMP and day after 1st IVMP, day before and day after 1st IVMP</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum norepinephrine levels Day 0 - Day 7</measure>
    <time_frame>7 days</time_frame>
    <description>Change in value of epinephrine between day before and sixth day after 1st pulse of IVMP</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum norepinephrine levels Day 0 - Day 2</measure>
    <time_frame>72 hours</time_frame>
    <description>Change in value of norepinephrine between day of 1st IVMP and day after 1st IVMP, day before and day after 1st IVMP</description>
  </other_outcome>
  <other_outcome>
    <measure>Urine potassium levels Day 1- Day 2</measure>
    <time_frame>48 hours</time_frame>
    <description>Change in value of epinephrine between day of 1st IVMP and day after 1st pulse of IVMP</description>
  </other_outcome>
  <other_outcome>
    <measure>Urine potassium levels Day 3 - Day 7</measure>
    <time_frame>5 days</time_frame>
    <description>Change in value of epinephrine between second and sixth day after 1st IVMP</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Graves Disease</condition>
  <condition>Graves Ophthalmopathy</condition>
  <condition>Heart Rhythm Disorder</condition>
  <condition>Hypertension</condition>
  <condition>Blood Pressure</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>active, moderate-to-severe GO</arm_group_label>
    <description>Each participant received IVMP according to EUGOGO recommendations (cumulative dose of methylprednisolone 4.5 g, treatment duration 12 weeks in single weekly intravenous pulses, first 6 weeks 0.5g of IVMP, next 6 weeks 0.25g of IVMP).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Methylprednisolone</intervention_name>
    <arm_group_label>active, moderate-to-severe GO</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      All assays were performed in sera obtained from venous blood samples and analysed immediately
      after blood sampling in The Endocrinology Research Laboratory in the hospital. All samples
      were centrifugated for plasma immediately after delivery (15 min; 1000 xg) and separated for
      both categories (EDTA and heparin) - 2 x 400 ul for test tubes with protease inhibitors and 4
      x 500 ul with no additives. Then all assays were frozen immediately to -70Â°C.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to the clinic for routine treatment of active, moderate-to-severe GO
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  active, moderate-to-severe GO according to EUGOGO classification

          -  euthyroidism

          -  completion of 12 IVMP pulses.

        Exclusion Criteria:

          -  cardiovascular morbidity (such as chronic heart failure and/or coronary heart disease)

          -  uncontrolled hypertension (defined as systolic blood pressure (SBP) more than 140 mmHg
             and/or diastolic blood pressure (DBP) more than 90 mmHg)

          -  contraindications to IVMP therapy

          -  previous GCs treatment in the last 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Warsaw</investigator_affiliation>
    <investigator_full_name>Piotr Miskiewicz</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graves Disease</mesh_term>
    <mesh_term>Graves Ophthalmopathy</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The collected data will be shared in a publication. It includes all laboratory results from all points of evaluation, results of 72-hour Holter ECG and 72-hour ABPM.</ipd_description>
    <ipd_time_frame>The results of the study will be published in 2020</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

